Literature DB >> 19940262

The cardiomyocyte lineage is critical for optimization of stem cell therapy in a mouse model of myocardial infarction.

Eric D Adler1, Vincent C Chen, Anne Bystrup, Aaron D Kaplan, Steven Giovannone, Karen Briley-Saebo, Wilson Young, Steve Kattman, Venkatesh Mani, Michael Laflamme, Wei-Zhong Zhu, Zahi Fayad, Gordon Keller.   

Abstract

We recently described a murine embryonic stem cell (ESC) line engineered to express the activated Notch 4 receptor in a tetracycline (doxcycline; Dox) regulated fashion (tet-notch4 ESCs). Notch 4 induction in Flk1(+) hematopoietic and vascular progenitors from this line respecified them to a cardiovascular fate. We reasoned that these cells would be ideal for evaluating the contribution of the cardiomyocyte and vascular lineages to the functional improvement noted following stem cell transplantation in infarcted hearts. Flk-1(+) Tet-notch4 cells from d 3 embryoid bodies exposed to doxycycline (Dox(+)) were compared to uninduced (Dox(-)) Flk-1(+) cells. Mice underwent transplantation of 5 x 10(5) Dox(+) cells, Dox(-)cells, or an equal volume of serum-free medium after surgically induced myocardial infarction. The mean ejection fraction was 59 + or - 15, 46 + or - 17, and 39 + or - 13% in the Dox(+), Dox(-), and serum-free medium groups, respectively (P<0.05 for the differences among all 3 groups). Immunohistochemistry of hearts injected with Dox(+) grafts expressed myocardial and vascular markers, whereas grafts of Dox(-) cells expressed primarily vascular markers. We conclude that cardiovascular progenitors are more effective than vascular progenitors in improving function after myocardial infarction. The transplantation of appropriate cell types is critical for maximizing the benefit of cardiovascular cell therapy.-Adler, E. D., Chen, V. C., Bystrup, A., Kaplan, A. D., Giovannone, S., Briley-Saebo, K., Young, W., Kattman, S., Mani, V., Laflamme, M., Zhu, W.-Z., Fayad, Z., Keller, G. The cardiomyocyte lineage is critical for optimization of stem cell therapy in a mouse model of myocardial infarction.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19940262      PMCID: PMC2845427          DOI: 10.1096/fj.09-135426

Source DB:  PubMed          Journal:  FASEB J        ISSN: 0892-6638            Impact factor:   5.191


  29 in total

Review 1.  Autologous cell transplantation for the treatment of damaged myocardium.

Authors:  Marc S Penn; Gary S Francis; Stephen G Ellis; James B Young; Patrick M McCarthy; Eric J Topol
Journal:  Prog Cardiovasc Dis       Date:  2002 Jul-Aug       Impact factor: 8.194

Review 2.  Cell-based approaches for cardiac repair.

Authors:  Michael Rubart; Loren J Field
Journal:  Ann N Y Acad Sci       Date:  2006-10       Impact factor: 5.691

3.  [Progress and clashes in stem cell therapy research].

Authors:  C L Mummery; L W van Laake
Journal:  Ned Tijdschr Geneeskd       Date:  2006-04-29

4.  Electromechanical integration of cardiomyocytes derived from human embryonic stem cells.

Authors:  Izhak Kehat; Leonid Khimovich; Oren Caspi; Amira Gepstein; Rona Shofti; Gil Arbel; Irit Huber; Jonathan Satin; Joseph Itskovitz-Eldor; Lior Gepstein
Journal:  Nat Biotechnol       Date:  2004-09-26       Impact factor: 54.908

5.  Cardiomyocytes derived from human embryonic stem cells in pro-survival factors enhance function of infarcted rat hearts.

Authors:  Michael A Laflamme; Kent Y Chen; Anna V Naumova; Veronica Muskheli; James A Fugate; Sarah K Dupras; Hans Reinecke; Chunhui Xu; Mohammad Hassanipour; Shailaja Police; Chris O'Sullivan; Lila Collins; Yinhong Chen; Elina Minami; Edward A Gill; Shuichi Ueno; Chun Yuan; Joseph Gold; Charles E Murry
Journal:  Nat Biotechnol       Date:  2007-08-26       Impact factor: 54.908

6.  Human cardiovascular progenitor cells develop from a KDR+ embryonic-stem-cell-derived population.

Authors:  Lei Yang; Mark H Soonpaa; Eric D Adler; Torsten K Roepke; Steven J Kattman; Marion Kennedy; Els Henckaerts; Kristina Bonham; Geoffrey W Abbott; R Michael Linden; Loren J Field; Gordon M Keller
Journal:  Nature       Date:  2008-04-23       Impact factor: 49.962

7.  Cyclin A2 mediates cardiomyocyte mitosis in the postmitotic myocardium.

Authors:  Hina W Chaudhry; Nurin H Dashoush; Haiying Tang; Ling Zhang; Xiangyuan Wang; Ed X Wu; Debra J Wolgemuth
Journal:  J Biol Chem       Date:  2004-05-24       Impact factor: 5.157

8.  Haematopoietic stem cells do not transdifferentiate into cardiac myocytes in myocardial infarcts.

Authors:  Charles E Murry; Mark H Soonpaa; Hans Reinecke; Hidehiro Nakajima; Hisako O Nakajima; Michael Rubart; Kishore B S Pasumarthi; Jitka Ismail Virag; Stephen H Bartelmez; Veronica Poppa; Gillian Bradford; Joshua D Dowell; David A Williams; Loren J Field
Journal:  Nature       Date:  2004-03-21       Impact factor: 49.962

9.  Engraftment of engineered ES cell-derived cardiomyocytes but not BM cells restores contractile function to the infarcted myocardium.

Authors:  Eugen Kolossov; Toktam Bostani; Wilhelm Roell; Martin Breitbach; Frank Pillekamp; Jens M Nygren; Philipp Sasse; Olga Rubenchik; Jochen W U Fries; Daniela Wenzel; Caroline Geisen; Ying Xia; Zhongju Lu; Yaqi Duan; Ralf Kettenhofen; Stefan Jovinge; Wilhelm Bloch; Heribert Bohlen; Armin Welz; Juergen Hescheler; Sten Eirik Jacobsen; Bernd K Fleischmann
Journal:  J Exp Med       Date:  2006-09-05       Impact factor: 14.307

10.  Cellular cardiomyoplasty with autologous skeletal myoblasts for ischemic heart disease and heart failure.

Authors:  Doris A Taylor
Journal:  Curr Control Trials Cardiovasc Med       Date:  2001
View more
  8 in total

Review 1.  Maturing human pluripotent stem cell-derived cardiomyocytes in human engineered cardiac tissues.

Authors:  Nicole T Feric; Milica Radisic
Journal:  Adv Drug Deliv Rev       Date:  2015-05-05       Impact factor: 15.470

Review 2.  The non-coding road towards cardiac regeneration.

Authors:  James E Hudson; Enzo R Porrello
Journal:  J Cardiovasc Transl Res       Date:  2013-12       Impact factor: 4.132

Review 3.  Embryonic template-based generation and purification of pluripotent stem cell-derived cardiomyocytes for heart repair.

Authors:  Pieterjan Dierickx; Pieter A Doevendans; Niels Geijsen; Linda W van Laake
Journal:  J Cardiovasc Transl Res       Date:  2012-07-18       Impact factor: 4.132

Review 4.  Stem cell-based cardiac tissue engineering.

Authors:  Sara S Nunes; Hannah Song; C Katherine Chiang; Milica Radisic
Journal:  J Cardiovasc Transl Res       Date:  2011-07-12       Impact factor: 4.132

5.  Label-free identification and characterization of human pluripotent stem cell-derived cardiomyocytes using second harmonic generation (SHG) microscopy.

Authors:  Samir Awasthi; Dennis L Matthews; Ronald A Li; Nipavan Chiamvimonvat; Deborah K Lieu; James W Chan
Journal:  J Biophotonics       Date:  2011-11-15       Impact factor: 3.207

Review 6.  Natural ECM as biomaterial for scaffold based cardiac regeneration using adult bone marrow derived stem cells.

Authors:  P Sreejit; R S Verma
Journal:  Stem Cell Rev Rep       Date:  2013-04       Impact factor: 5.739

Review 7.  Concise review: Engineering myocardial tissue: the convergence of stem cells biology and tissue engineering technology.

Authors:  Jan Willem Buikema; Peter Van Der Meer; Joost P G Sluijter; Ibrahim J Domian
Journal:  Stem Cells       Date:  2013-12       Impact factor: 6.277

8.  Doing the dirty work: progress in the search for a reliable protocol for cardiomyogenesis.

Authors:  Jennifer K Redig; Eric Adler
Journal:  Stem Cell Res Ther       Date:  2011-08-15       Impact factor: 6.832

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.